Salud financiera de hoja de balance de Silo Pharma

Salud financiera controles de criterios 6/6

Silo Pharma tiene un patrimonio de los accionistas total de $6.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $8.6M y $1.8M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$8.02m
Patrimonio	US$6.78m
Total pasivo	US$1.78m
Activos totales	US$8.57m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Oct 20

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Oct 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($8.3M) de SILO superan a sus pasivos a corto plazo ($1.0M).

Pasivo a largo plazo: Los activos a corto plazo de SILO ($8.3M) superan a sus pasivos a largo plazo ($739.6K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: SILO está libre de deudas.

Reducción de la deuda: SILO no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 8.4%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: SILO tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: SILO dispone de suficiente cash runway para 2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 36.4% cada año.

Salud financiera de hoja de balance de Silo Pharma

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Silo Pharma, Inc. Announces Positive Results for Novel Spc-15 Treatment Targeting Stress-Related Disorders

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)

Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023)

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. announced that it has received $2.077409 million in funding

New minor risk - Shareholder dilution

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million.

New major risk - Share price stability

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment

Full year 2023 earnings: EPS misses analyst expectations

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA

Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease

Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021)

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's

Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares.

Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021)

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Investor sentiment improved over the past week

High number of new and inexperienced directors

Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore

Silo Pharma Inc. announced that it expects to receive $4.276 million in funding

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board

Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease

Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

Silo Pharma, Inc. Appoints Kevin Muñoz to Board of Directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera